Categories: News

Conference Call on Interim Report

GOTHENBURG, SE / ACCESSWIRE / October 7, 2021 / XVIVO Perfusion AB (STO:XVIVO) (LSE:0RKL) (FRA:3XV)

Invitation to attend XVIVO’s conference call regarding the presentation of the interim report July – September 2021. The presentation will be held in English.

Time: Thursday, October 21, 2021 at 2.00 p.m. CET
Information regarding the conference can be found under the following link:
https://onlinexperiences.com/Launch/QReg/ShowUUID=07001B8B-3391-4BA9-8F3E-BBE54EDF834E .

Phone numbers to the conference:
Sweden: +46 856642651 PIN: 13466713#
UK: +44 3333000804 PIN: 13466713#
US: +1 6319131422 PIN: 13466713#
Conference name: XVIVO Group Interim Report Q3, conference ID: EV00128347

Participants from XVIVO:
Dag Andersson, CEO
Kristoffer Nordström, CFO

The press release for XVIVO’s interim report July-September 2021 will be released on October 21, 2021 at 7:30 a.m. CET.

Before the conference call, slides will be available at the company web page, https://www.xvivoperfusion.com/corporate/financial-presentations/earnings-calls/

October 7, 2021
Gothenburg
XVIVO Perfusion AB (publ)

For further information, please contact:

Dag Andersson, CEO, +46 76 643 30 31, e-mail: dag.andersson@xvivogroup.com
Kristoffer Nordström, CFO, +46 73 519 21 64, e-mail: kristoffer.nordstrom@xvivogroup.com

About Us

Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs – so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Nasdaq and has the ticker symbol XVIVO. More information can be found on the website www.xvivogroup.com.

Attachments

Conference call on Interim Report

SOURCE: XVIVO Perfusion AB

View source version on accesswire.com:
https://www.accesswire.com/667197/Conference-Call-on-Interim-Report

Staff

Recent Posts

Is The DEA in Systemic Collapse: Corruption, Constitutional Violations, and a Seven-Year War Against Marijuana Medical Science

The DEA was created to combat cartel trafficking, protect public health, and ensure researchers have…

8 hours ago

Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease

CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology…

8 hours ago

Secura Bio Presents Extended Follow Up Analyses from Phase 2 PRIMO Trial in Patients with Relapsed/Refractory peripheral T-cell lymphoma at the 2025 American Society of Hematology Meeting

Longer-term analyses reinforce duvelisib’s activity across treatment-experienced PTCL populations, including patients with ≥3 prior lines…

8 hours ago